These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37409123)

  • 1. Imidazoquinolines with improved pharmacokinetic properties induce a high IFNα to TNFα ratio
    Keppler M; Straß S; Geiger S; Fischer T; Späth N; Weinstein T; Schwamborn A; Guezguez J; Guse JH; Laufer S; Burnet M
    Front Immunol; 2023; 14():1168252. PubMed ID: 37409123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.
    Gibson SJ; Lindh JM; Riter TR; Gleason RM; Rogers LM; Fuller AE; Oesterich JL; Gorden KB; Qiu X; McKane SW; Noelle RJ; Miller RL; Kedl RM; Fitzgerald-Bocarsly P; Tomai MA; Vasilakos JP
    Cell Immunol; 2002; 218(1-2):74-86. PubMed ID: 12470615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
    Hunt JR; Kleindl PA; Moulder KR; Prisinzano TE; Forrest ML
    Bioorg Med Chem Lett; 2020 Jan; 30(2):126788. PubMed ID: 31784317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of Human γδ T Cells: Modulation by Toll-Like Receptor 8 Ligands and Role of Monocytes.
    Serrano R; Wesch D; Kabelitz D
    Cells; 2020 Mar; 9(3):. PubMed ID: 32183240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resiquimod inhibits Newcastle disease virus replication by modulating host cytokines: An understanding towards its possible therapeutics.
    Gupta A; Deka P; Kumar S
    Cytokine; 2020 Jan; 125():154811. PubMed ID: 31446178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Imidazoquinoline Toll-Like Receptor-7/8 Agonist Hybrid-2 Potently Induces Cytokine Production by Human Newborn and Adult Leukocytes.
    Ganapathi L; Van Haren S; Dowling DJ; Bergelson I; Shukla NM; Malladi SS; Balakrishna R; Tanji H; Ohto U; Shimizu T; David SA; Levy O
    PLoS One; 2015; 10(8):e0134640. PubMed ID: 26274907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral delivery of TransCon
    Zúñiga LA; Leßmann T; Uppal K; Bisek N; Hong E; Rasmussen CE; Karlsson JJ; Zettler J; Holten-Andersen L; Bang K; Thakar D; Lee YC; Martinez S; Sabharwal SS; Stark S; Faltinger F; Kracker O; Weisbrod S; Müller R; Voigt T; Bigott K; Tabrizifard M; Breinholt VM; Mirza AM; Rosen DB; Sprogøe K; Punnonen J
    Cancer Cell Int; 2022 Sep; 22(1):286. PubMed ID: 36123697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
    Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
    J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
    Vasilakos JP; Tomai MA
    Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The TLR7/8 ligand resiquimod targets monocyte-derived dendritic cell differentiation via TLR8 and augments functional dendritic cell generation.
    Hackstein H; Knoche A; Nockher A; Poeling J; Kubin T; Jurk M; Vollmer J; Bein G
    Cell Immunol; 2011; 271(2):401-12. PubMed ID: 21889130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides.
    Shinchi H; Crain B; Yao S; Chan M; Zhang SS; Ahmadiiveli A; Suda Y; Hayashi T; Cottam HB; Carson DA
    Bioconjug Chem; 2015 Aug; 26(8):1713-23. PubMed ID: 26193334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines.
    Gorden KK; Qiu X; Battiste JJ; Wightman PP; Vasilakos JP; Alkan SS
    J Immunol; 2006 Dec; 177(11):8164-70. PubMed ID: 17114492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and characterization of PEGylated toll like receptor 7 ligands.
    Chan M; Hayashi T; Mathewson RD; Yao S; Gray C; Tawatao RI; Kalenian K; Zhang Y; Hayashi Y; Lao FS; Cottam HB; Carson DA
    Bioconjug Chem; 2011 Mar; 22(3):445-54. PubMed ID: 21338093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines.
    Shukla NM; Mutz CA; Malladi SS; Warshakoon HJ; Balakrishna R; David SA
    J Med Chem; 2012 Feb; 55(3):1106-16. PubMed ID: 22239408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLR7 is involved in sequence-specific sensing of single-stranded RNAs in human macrophages.
    Gantier MP; Tong S; Behlke MA; Xu D; Phipps S; Foster PS; Williams BR
    J Immunol; 2008 Feb; 180(4):2117-24. PubMed ID: 18250417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resiquimod: a new topical immune-response modifier for the treatment of actinic keratosis.
    Farr MA; Joshi TP; Lewis DJ
    Expert Opin Emerg Drugs; 2021 Dec; 26(4):433-434. PubMed ID: 34749552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes.
    Dowling DJ; Tan Z; Prokopowicz ZM; Palmer CD; Matthews MA; Dietsch GN; Hershberg RM; Levy O
    PLoS One; 2013; 8(3):e58164. PubMed ID: 23483986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy with TLR7 agonists induces lymphopenia: correlating pharmacology to mechanism in a mouse model.
    Perkins H; Khodai T; Mechiche H; Colman P; Burden F; Laxton C; Horscroft N; Corey T; Rodrigues D; Rawal J; Heyen J; Fidock M; Westby M; Bright H
    J Clin Immunol; 2012 Oct; 32(5):1082-92. PubMed ID: 22476912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
    Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
    Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.